246 related articles for article (PubMed ID: 21623166)
1. Inhibition of N-myc downstream-regulated gene 2 in prostatic carcinoma.
Yu C; Wu G; Dang N; Zhang W; Zhang R; Yan W; Zhao Y; Gao L; Wang Y; Beckwith N; Yuan J; Yao L
Cancer Biol Ther; 2011 Aug; 12(4):304-13. PubMed ID: 21623166
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of N-Myc downstream-regulated gene 2 (NDRG2) regulates the proliferation and invasion of bladder cancer cells in vitro and in vivo.
Li R; Yu C; Jiang F; Gao L; Li J; Wang Y; Beckwith N; Yao L; Zhang J; Wu G
PLoS One; 2013; 8(10):e76689. PubMed ID: 24146910
[TBL] [Abstract][Full Text] [Related]
3. Suppression of invasion and metastasis of prostate cancer cells by overexpression of NDRG2 gene.
Gao L; Wu GJ; Liu XW; Zhang R; Yu L; Zhang G; Liu F; Yu CG; Yuan JL; Wang H; Yao LB
Cancer Lett; 2011 Nov; 310(1):94-100. PubMed ID: 21741166
[TBL] [Abstract][Full Text] [Related]
4. Suppressor of activator protein-1 regulated by interferon expression in prostate cancer tissues and cells.
Zhang S; Rong P; Chen Q; Wang W
Life Sci; 2019 Sep; 232():116626. PubMed ID: 31276688
[TBL] [Abstract][Full Text] [Related]
5. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
7. TUG1 promotes the development of prostate cancer by regulating RLIM.
Guo BH; Zhao Q; Li HY
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):1926-1933. PubMed ID: 30915735
[TBL] [Abstract][Full Text] [Related]
8. IgG gene expression and its possible significance in prostate cancers.
Liu Y; Chen Z; Niu N; Chang Q; Deng R; Korteweg C; Gu J
Prostate; 2012 May; 72(6):690-701. PubMed ID: 22430367
[TBL] [Abstract][Full Text] [Related]
9. Suppression of microRNA-454 impedes the proliferation and invasion of prostate cancer cells by promoting N-myc downstream-regulated gene 2 and inhibiting WNT/β-catenin signaling.
Fu Q; Gao Y; Yang F; Mao T; Sun Z; Wang H; Song B; Li X
Biomed Pharmacother; 2018 Jan; 97():120-127. PubMed ID: 29080452
[TBL] [Abstract][Full Text] [Related]
10. TAZ is overexpressed in prostate cancers and regulates the proliferation, migration and apoptosis of prostate cancer PC3 cells.
Lin M; Bu C; He Q; Gu J; Wang H; Feng N; Jiang SW
Oncol Rep; 2020 Aug; 44(2):747-756. PubMed ID: 32468018
[TBL] [Abstract][Full Text] [Related]
11. CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.
Guo Z; Liu D; Su Z
Tumour Biol; 2015 Jun; 36(6):4777-83. PubMed ID: 25636449
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
13. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells.
Hu F; Yuan W; Wang X; Sheng Z; Yuan Y; Qin C; He C; Xu T
Clin Transl Oncol; 2015 Aug; 17(8):632-9. PubMed ID: 25990505
[TBL] [Abstract][Full Text] [Related]
14. N-myc downstream-regulated gene 2 expression is associated with glucose transport and correlated with prognosis in breast carcinoma.
Ma J; Liu W; Guo H; Li S; Cao W; Du X; Lei S; Hou W; Xiong L; Yao L; Li N; Li Y
Breast Cancer Res; 2014 Mar; 16(2):R27. PubMed ID: 24636131
[TBL] [Abstract][Full Text] [Related]
15. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
[TBL] [Abstract][Full Text] [Related]
16. Identification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer.
Qiu J; Peng S; Si-Tu J; Hu C; Huang W; Mao Y; Qiu W; Li K; Wang D
BMC Cancer; 2017 May; 17(1):360. PubMed ID: 28532481
[TBL] [Abstract][Full Text] [Related]
17. The tumor suppressing effects of QKI-5 in prostate cancer: a novel diagnostic and prognostic protein.
Zhao Y; Zhang G; Wei M; Lu X; Fu H; Feng F; Wang S; Lu W; Wu N; Lu Z; Yuan J
Cancer Biol Ther; 2014 Jan; 15(1):108-18. PubMed ID: 24153116
[TBL] [Abstract][Full Text] [Related]
18. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
[TBL] [Abstract][Full Text] [Related]
19. Low expression of N-myc downstream-regulated gene 2 in oesophageal squamous cell carcinoma correlates with a poor prognosis.
Cao W; Yu G; Lu Q; Zhang J
BMC Cancer; 2013 Jun; 13():305. PubMed ID: 23800335
[TBL] [Abstract][Full Text] [Related]
20. Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer.
Okada Y; Sonoshita M; Kakizaki F; Aoyama N; Itatani Y; Uegaki M; Sakamoto H; Kobayashi T; Inoue T; Kamba T; Suzuki A; Ogawa O; Taketo MM
Cancer Sci; 2017 Apr; 108(4):744-752. PubMed ID: 28178391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
